Preventing relapse in schizophrenia needs better evidence

Affiliations

¹ WHO Collaborating Centre for Research and Training in Mental Health and Service Evaluation, Department of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry, University of Verona, Verona 37134, Italy. Electronic address: giovanni.ostuzzi@univr.it.
² WHO Collaborating Centre for Research and Training in Mental Health and Service Evaluation, Department of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry, University of Verona, Verona 37134, Italy.

Comment

Giovanni Ostuzzi et al. Lancet. 2022.

. 2022 Feb 26;399(10327):773-775.

doi: 10.1016/S0140-6736(21)02142-5.

¹ WHO Collaborating Centre for Research and Training in Mental Health and Service Evaluation, Department of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry, University of Verona, Verona 37134, Italy. Electronic address: giovanni.ostuzzi@univr.it.
² WHO Collaborating Centre for Research and Training in Mental Health and Service Evaluation, Department of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry, University of Verona, Verona 37134, Italy.

No abstract available

Conflict of interest statement

We declare no competing interests.

Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis.
Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, Arndt T, Bäckers L, Rothe P, Cipriani A, Davis J, Salanti G, Leucht S. Huhn M, et al. Lancet. 2019 Sep 14;394(10202):939-951. doi: 10.1016/S0140-6736(19)31135-3. Epub 2019 Jul 11. Lancet. 2019. PMID: 31303314 Free PMC article.